Pharmala Biotech Holdings Inc
Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.
Market Cap & Net Worth: Pharmala Biotech Holdings Inc (MDXXF)
Pharmala Biotech Holdings Inc (OTCQB:MDXXF) has a market capitalization of $12.75 Million ($12.75 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #29051 globally and #9644 in its home market, demonstrating a -3.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharmala Biotech Holdings Inc's stock price $0.12 by its total outstanding shares 108887215 (108.89 Million).
Pharmala Biotech Holdings Inc Market Cap History: 2023 to 2025
Pharmala Biotech Holdings Inc's market capitalization history from 2023 to 2025. Data shows change from $3.44 Million to $12.75 Million (-40.27% CAGR).
Pharmala Biotech Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharmala Biotech Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.06x
Pharmala Biotech Holdings Inc's market cap is 21.06 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $3.44 Million | $532.00K | -$779.81K | 6.47x | N/A |
| 2024 | $22.54 Million | $1.04 Million | -$823.60K | 21.77x | N/A |
| 2025 | $12.75 Million | $605.50K | -$2.18 Million | 21.06x | N/A |
Competitor Companies of MDXXF by Market Capitalization
Companies near Pharmala Biotech Holdings Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Pharmala Biotech Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pharmala Biotech Holdings Inc Historical Marketcap From 2023 to 2025
Between 2023 and today, Pharmala Biotech Holdings Inc's market cap moved from $3.44 Million to $ 12.75 Million, with a yearly change of -40.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $12.75 Million | -43.43% |
| 2024 | $22.54 Million | +555.06% |
| 2023 | $3.44 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pharmala Biotech Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.75 Million USD |
| MoneyControl | $12.75 Million USD |
| MarketWatch | $12.75 Million USD |
| marketcap.company | $12.75 Million USD |
| Reuters | $12.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.